Yun Yang

发表

Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.

Liu-fang Gu, Wang-gang Zhang, Fangxia Wang, 2016, Leukemia research.

Management of cytokine release syndrome related to CAR-T cell therapy

B. Lei, Wanggang Zhang, Liu-fang Gu, 2019, Frontiers of Medicine.

Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine

Wanggang Zhang, A. He, Yun Yang, 2012, Medical Oncology.

Expression profile analysis of long non‐coding RNA in acute myeloid leukemia by microarray and bioinformatics

Tian Liu, Liu-fang Gu, Fangxia Wang, 2018, Cancer science.

Detection of serum tumor markers in multiple myeloma using the CLINPROT system

Juan Yang, Wanggang Zhang, A. He, 2012, International Journal of Hematology.

granulocyte-colony stimulating factor (G-CSF) (CAG) priming regimen is an effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). G‐CSF influences the bone marrow microenvironment (BMM) by mobilizing regulatory T cells (T

Huan Yao, Wanggang Zhang, Yun Yang, 2018 .

Using Circ-ANAPC7 as a Novel Type of Biomarker in the Monitoring of Acute Myeloid Leukemia

A. He, Yun Yang, Hongli Chen, 2019, Acta Haematologica.

Granulocyte colony stimulating factor priming chemotherapy is more effective than standard chemotherapy as salvage therapy in relapsed acute myeloid leukemia

Wanggang Zhang, Fangxia Wang, Xing-mei Cao, 2018, Medicina Clínica (English Edition).

Granulocyte colony stimulating factor priming chemotherapy is more effective than standard chemotherapy as salvage therapy in relapsed acute myeloid leukemia.

Wanggang Zhang, Fangxia Wang, Xing-mei Cao, 2017, Medicina clinica.

Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens

Wanggang Zhang, Fangxia Wang, A. He, 2019, Hematology.

Comparison of porcine anti‐human lymphocyte globulin and rabbit anti‐human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single‐center study

Wanggang Zhang, Xing-mei Cao, Yin-xia Chen, 2016, European journal of haematology.

Use of intravenous immunoglobulin in the treatment of paroxysmal nocturnal hemoglobinuria : a case report and literature review

Wanggang Zhang, Fangxia Wang, A. He, 2018 .

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Saijuan Chen, Hua Jiang, Jian-yong Li, 2022, Journal of Hematology & Oncology.

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

B. Lei, Y. Geng, Zong-fang Li, 2018, Journal of Hematology & Oncology.

Focusing on long non‐coding RNA dysregulation in newly diagnosed multiple myeloma

Yan Peng, Fangxia Wang, A. He, 2018, Life sciences.

A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6.

Xiao-rong Ma, Yun Yang, Su-hu Liu, 2005, Leukemia research.

Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma

Jinsong Hu, Fangxia Wang, A. He, 2020, Cell Stress and Chaperones.

Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling

Juan Yang, Wanggang Zhang, A. He, 2013, Proteome Science.

A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma

R. Liu, Jinsong Hu, A. He, 2023, Frontiers in Oncology.

High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study

Wanggang Zhang, Xing-mei Cao, Yin-xia Chen, 2016, Medical science monitor : international medical journal of experimental and clinical research.

Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

B. Lei, Liu-fang Gu, Fangxia Wang, 2020 .

Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia

Wanggang Zhang, Fangxia Wang, A. He, 2021, Journal of immunotherapy.

Circ-ANAPC7 is Upregulated in Acute Myeloid Leukemia and Appears to Target the MiR-181 Family

Yuqiang Ji, Tian Liu, Juan Yang, 2018, Cellular Physiology and Biochemistry.

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Zong-fang Li, B. Lei, Y. Geng, 2018, Blood.

Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma

Fangxia Wang, A. He, Yun Yang, 2019, Clinical Proteomics.

Prokaryotic expression of MLAA-34 and generation of a novel human ScFv against MLAA-34 by phage display technology

Yang Zhang, Wanggang Zhang, A. He, 2017, Oncotarget.

Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling

Yang Zhang, Juan Yang, Wanggang Zhang, 2013, Proteome Science.

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

Yang Zhang, Juan Yang, Wanggang Zhang, 2014, Proteome Science.

Targeted silencing of genes related to acute monocytic leukaemia by CpG(B)-MLAA-34 siRNA conjugates

Wanggang Zhang, A. He, Xiao-rong Ma, 2019, Journal of drug targeting.

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

B. Lei, Y. Geng, Zong-fang Li, 2019, Blood.

Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma

Fangxia Wang, A. He, Yun Yang, 2020, Cell Stress and Chaperones.

Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma

Fangxia Wang, A. He, Yun Yang, 2019, Clinical Proteomics.

N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition

R. Liu, Hui Liu, A. He, 2023, Oncogene.

Pretreatment platelet-lymphocyte ratio versus neutrophil-lymphocyte ratio in the prognosis of multiple myeloma : a single center retrospective study

Wanggang Zhang, A. He, Jie Liu, 2019 .

Deregulated Expression of Long Non-Coding RNA AC092580.4 in Acute Myeloid Leukemia

Fangxia Wang, A. He, Baiyan Wang, 2018, Blood.

MLAA-34 knockdown shows enhanced antitumor activity via JAK2/STAT3 signaling pathway in acute monocytic leukemia

Yanping Zhang, B. Lei, Xin Meng, 2020, Journal of Cancer.

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Liu-fang Gu, Fangxia Wang, Xing-mei Cao, 2022, Journal of Medical Case Reports.

Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model

Huan Yao, Wanggang Zhang, Yun Yang, 2018, Oncology letters.

Indoleamine 2, 3-dioxygenase expression in cells of human acute monocyte leukemia (M(5)) and acute lymphocyte leukemia and therapeutic effect of its inhibitor 1-methyl tryptophan.

Yin-xia Chen, JingKang Sun, Yun Yang, 2007, Zhongguo shi yan xue ye xue za zhi.